The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA
Open accessAbstract
Self-amplifying RNA (saRNA) is a cutting-edge platform for both nucleic acid vaccines and therapeutics. saRNA is self-adjuvanting, as it activates types I and III interferon (IFN), which enhances the immunogenicity of RNA vaccines but can also lead to inhibition of translation. In this study, we screened a library of saRNA constructs with cis -encoded innate inhibiting proteins (IIPs) and determined the effect on protein expression and immunogenicity. We observed that the PIV-5 V and Middle East respiratory syndrome coronavirus (MERS-CoV) ORF4a proteins enhance protein expression 100- to 500-fold in vitro in IFN-competent HeLa and MRC5 cells. We found that the MERS-CoV ORF4a protein partially abates dose nonlinearity in vivo , and that ruxolitinib, a potent Janus kinase (JAK)/signal transducer and activator of transcription (STAT) inhibitor, but not the IIPs, enhances protein expression of saRNA in vivo . Both the PIV-5 V and MERS-CoV ORF4a proteins were found to enhance the percentage of resident cells in human skin explants expressing saRNA and completely rescued dose nonlinearity of saRNA. Finally, we observed that the MERS-CoV ORF4a increased the rabies virus ( RABV )-specific immunoglobulin G (IgG) titer and neutralization half-maximal inhibitory concentration (IC 50 ) by ∼10-fold in rabbits, but not in mice or rats. These experiments provide a proof of concept that IIPs can be directly encoded into saRNA vectors and effectively abate the nonlinear dose dependency and enhance immunogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous efforts to decrease the immunogenicity of saRNA focused on sequence evolution, co-expression of viral inhibitory proteins and optimization of the delivery vehicle16–18.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“Thus, incorporation of encoded modulators of human PRR or of a wider range of potential modifications may positively affect immunogenicity and efficacy of saRNA vaccines.443,444”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [444]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Siu, K., Yeung, M. L., Kok, K., Yuen, K., Kew, C., Lui, P., Chan, C., Tse, H., Woo, P. C. Y., Yuen, K., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03649-13 · Cited by 179
Retracted(2008) · Journal of Machine Learning Research · Cited by 33,051
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Vaure, C., & Liu, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00316 · Cited by 842
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675
Hemmi, H., Takeuchi, O., Sato, S., Yamamoto, M., Kaisho, T., Sanjo, H., Kawai, T., Hoshino, K., Takeda, K., & Akira, S. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040520 · Cited by 576
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530
Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338
The eIF‐2α kinases and the control of protein synthesis 1
de Haro, C., Méndez, R., & Santoyo‐López, J. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.12.8903508 · Cited by 298
Yang, Y., Zhang, L., Geng, H., Deng, Y. L., Huang, B., Yin, G., Zhao, Z., & Tan, W. (2013) · Protein & Cell · doi:10.1007/s13238-013-3096-8 · Cited by 273
The Many Faces of the Flavivirus NS5 Protein in Antagonism of Type I Interferon Signaling
Best, S. M. (2016) · Journal of Virology · doi:10.1128/jvi.01970-16 · Cited by 248
A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223
Gene expression variability across cells and species shapes innate immunity
Hagai, T., Chen, X., Miragaia, R. J., Rostom, R., Gomes, T., Kunowska, N., Henriksson, J., Park, J.-E., Proserpio, V., Donati, G., et al. (2018) · Nature · doi:10.1038/s41586-018-0657-2 · Cited by 220
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01186 · Cited by 212
Pepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208
Blakney, A. K., McKay, P. F., Yus, B. I., Aldon, Y., & Shattock, R. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0095-2 · Cited by 206
Self-citationRabouw, H. H., Langereis, M. A., Knaap, R. C. M., Dalebout, T. J., Cantón, J., Sola, I., Enjuanes, L., Bredenbeek, P. J., Kikkert, M., de Groot, R. J., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005982 · Cited by 193
Functions of the influenza A virus NS1 protein in antiviral defense
Krug, R. M. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.01.007 · Cited by 188
Xing, J., Wang, S., Lin, R., Mossman, K. L., & Zheng, C. (2012) · Journal of Virology · doi:10.1128/jvi.06713-11 · Cited by 178
mRNA-Based Protein Replacement Therapy for the Heart
Magadum, A., Kaur, K., & Zangi, L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.018 · Cited by 176
Perri, S., Greer, C. E., Thudium, K., Doe, B., Legg, H., Liu, H., Romero, R. E., Tang, Z., Bin, Q., Dubensky, T. W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.19.10394-10403.2003 · Cited by 172
Werme, K., Wigerius, M., & Johansson, M. (2008) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.01076.x · Cited by 164
Blakney, A. K., Zhu, Y., McKay, P. F., Bouton, C. R., Yeow, J., Tang, J., Hu, K., Samnuan, K., Grigsby, C. L., Shattock, R. J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00326 · Cited by 155
Self-citationLarge Animal Models for Vaccine Development and Testing
Gerdts, V., Wilson, H. L., Meurens, F., den Hurk, S. V. D. L., Wilson, D. J., Walker, S., Wheler, C. L., Townsend, H. G. G., & Potter, A. A. (2015) · ILAR Journal · doi:10.1093/ilar/ilv009 · Cited by 134
Lui, P., Wong, L.-Y. R., Fung, C.-L., Siu, K., Yeung, M. L., Yuen, K., Chan, C., Woo, P. C. Y., Yuen, K., & Jin, D. (2016) · Emerging Microbes & Infections · doi:10.1038/emi.2016.33 · Cited by 133
MERS-CoV 4b protein interferes with the NF-κB-dependent innate immune response during infection
Cantón, J., Fehr, A. R., Fernández‐Delgado, R., Gutierrez-Alvarez, F. J., Sánchez-Aparicio, M. T., García‐Sastre, A., Perlman, S. M., Enjuanes, L., & Sola, I. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006838 · Cited by 122
Comar, C. E., Goldstein, S. A., Li, Y., Yount, B. L., Baric, R. S., & Weiss, S. R. (2019) · mBio · doi:10.1128/mbio.00319-19 · Cited by 113
RNase L: Its biological roles and regulation
Liang, S.-L., Quirk, D. J., & Zhou, A. (2006) · IUBMB Life · doi:10.1080/15216540600838232 · Cited by 109
Modulation of the immune response by Middle East respiratory syndrome coronavirus
Shokri, S., Mahmoudvand, S., Taherkhani, R., & Farshadpour, F. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27155 · Cited by 90
Beißert, T., Koste, L., Perković, M., Walzer, K. C., Erbar, S., Selmi, A., Diken, M., Kreiter, S., Türeci, Ö., & Şahin, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.121 · Cited by 81
HAIG, McInnes, C. J., Thomson, WOOD, BUNYAN, & Mercer, A. A. (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00438.x · Cited by 80
Mechanisms underlying the inhibition of interferon signaling by viruses
Devasthanam, A. S. (2014) · Virulence · doi:10.4161/viru.27902 · Cited by 79
Ramachandran, A., & Horvath, C. M. (2010) · Journal of Virology · doi:10.1128/jvi.01375-10 · Cited by 74
Blakney, A. K., Yilmaz, G., McKay, P. F., Becer, C. R., & Shattock, R. J. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00429 · Cited by 74
Self-citationBlakney, A. K., McKay, P. F., Ibarzo Yus, B., Hunter, J. E., Dex, E. A., & Shattock, R. J. (2019) · ACS Nano · doi:10.1021/acsnano.9b01774 · Cited by 73
Self-citationKim, D. Y., Atasheva, S., McAuley, A. J., Plante, J. A., Frolova, E. I., Beasley, D. W. C., & Frolov, I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408677111 · Cited by 57
Suppression of PACT-Induced Type I Interferon Production by Herpes Simplex Virus 1 Us11 Protein
Kew, C., Lui, P., Chan, C., Liu, X., Au, S. W. N., Mohr, I., Jin, D., & Kok, K. (2013) · Journal of Virology · doi:10.1128/jvi.02564-13 · Cited by 57
Blakney, A. K., McKay, P. F., Christensen, D., Yus, B. I., Aldon, Y., Follmann, F., & Shattock, R. J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.043 · Cited by 48
Self-citationRodriguez, K. R., & Horvath, C. M. (2014) · Journal of Virology · doi:10.1128/jvi.00737-14 · Cited by 47
Structural components for amplification of positive and negative strand VEEV splitzicons
Blakney, A. K., McKay, P. F., & Shattock, R. J. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00071 · Cited by 47
Self-citationMEURS, E. F., Hovanessian, A. G., & Montagnier, L. (1981) · Journal of Interferon Research · doi:10.1089/jir.1981.1.219 · Cited by 43
Zhang, M., Liu, Y., Wang, P., Guan, X., He, S., Luo, S., Li, C., Hu, K., Jin, W., Du, T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401538 · Cited by 42
Self-citationStrain Differences of Interferon–Generating Capacity and Resistance in Toxoplasma–Infected Mice
Shirahata, T., Mori, A., Ishikawa, H., & Goto, M. (1986) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1986.tb03051.x · Cited by 38
Blakney, A. K., Abdouni, Y., Yilmaz, G., Liu, R., McKay, P. F., Bouton, C. R., Shattock, R. J., & Becer, C. R. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00445 · Cited by 36
Self-citationHorscroft, N., Bellows, D., Ansari, I. H., Lai, V. C. H., Dempsey, S., Liang, D., Donis, R. O., Zhong, W., & Hong, Z. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2788-2796.2005 · Cited by 35
Production and action of interferon in HeLa cells
Cantell, K. (1961) · Archives of Virology · doi:10.1007/bf01241887 · Cited by 33
What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?Preprint
Jameson, S. C., & Masopust, D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a029132 · Cited by 33
Gurnani, P., Blakney, A. K., Terracciano, R., Petch, J. E., Blok, A. J., Bouton, C. R., McKay, P. F., Shattock, R. J., & Alexander, C. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00698 · Cited by 33
Self-citationBatool, M., Shah, M., Patra, M. C., Yesudhas, D., & Choi, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-11736-6 · Cited by 29
Darweesh, M. F., Rajput, M., Braun, L. J., Rohila, J. S., & Chase, C. C. L. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.05.047 · Cited by 29
Badamchi-Zadeh, A., McKay, P. F., Holland, M. J., Paes, W., Brzozowski, A. M., Lacey, C., Follmann, F., Tregoning, J. S., & Shattock, R. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141209 · Cited by 23
Self-citationSaviano, F., Lovato, T., Russo, A., Russo, G., Bouton, C. R., Shattock, R. J., Alexander, C., Quaglia, F., Blakney, A. K., Gurnani, P., et al. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00942c · Cited by 23
Self-citationKraus, T. A., Garza, L., & Horvath, C. M. (2007) · Virology · doi:10.1016/j.virol.2007.10.001 · Cited by 22
Liu, Y., Chin, J. M., Choo, E. L., & Phua, K. K. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-48559-6 · Cited by 22
Regulation of PACT-Mediated Protein Kinase Activation by the OV20.0 Protein of Orf Virus
Tseng, Y., Liao, G., Sen, G. C., Lin, F., & Hsu, W. (2015) · Journal of Virology · doi:10.1128/jvi.01739-15 · Cited by 20
Fitzgerald, M. E., Rawling, D., Potapova, O., Ren, X., Kohlway, A. S., & Pyle, A. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw816 · Cited by 19
Constitutively Active MDA5 Proteins Are Inhibited by Paramyxovirus V Proteins
Mandhana, R., Qian, L. K., & Horvath, C. M. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0049 · Cited by 9
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
An Update on Self-Amplifying mRNA Vaccine Development
Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288
Self-citationPollock, K. M., Cheeseman, H. M., Szubert, A. J., Libri, V., Boffito, M., Owen, D., Bern, H., McFarlane, L. R., O'Hara, J., Lemm, N.-M., et al. (2022) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101262 · Cited by 173
Self-citationMinnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157
Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
Blakney, A. K., McKay, P. F., Hu, K., Samnuan, K., Jain, N., Brown, A., Thomas, A. M., Rogers, P., Polra, K., Sallah, H., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.029 · Cited by 137
Self-citation
Metadata
- Authors
- Blakney, A. K., McKay, P. F., Bouton, C. R., Hu, K., Samnuan, K., & Shattock, R. J.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Blakney, Anna K.
- Shattock, Robin J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 29
- Issue
- 3
- Pages
- 1174-1185
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC7935664
- OpenAlex
- W3115814127
- Cited by
- 105
- References
- 60
- Citations by year
- 2026: 23 · 2025: 22 · 2024: 23 · 2023: 15 · 2022: 16 · 2021: 6
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- H2020 Marie Skłodowska-Curie Actions
- Engineering and Physical Sciences Research Council
- Whitaker International Fellows and Scholars Program
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- self-amplifying RNA, rabies virus, interferon, protein synthesis inhibition, ruxolitinib, JAK/STAT inhibition, rabies virus neutralizing antibodies
- MeSH terms
- Immunogenicity, Vaccine, mRNA Vaccines, Animals, Cell Line, Encephalitis Virus, Venezuelan Equine, Fibroblasts, Gene Expression Regulation, HeLa Cells, Humans, Immunoglobulin G, Immunity, Innate, Nitriles, Pyrazoles, Pyrimidines, Rabbits, Rabies virus, Protein Biosynthesis, Vaccines, Synthetic, Viral Envelope Proteins, Signal Transduction, NF-kappa B, Parainfluenza Virus 5, STAT Transcription Factors, Interferon Regulatory Factor-3, Mice, Rats, Janus Kinases, Host-Pathogen Interactions, Middle East Respiratory Syndrome Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
